-
EP2128174
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2128174
| EP2128174 - Multimeric forms of TNF superfamily ligands [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 16.11.2012 Database last updated on 21.03.2026 | Most recent event Tooltip | 16.11.2012 | Application deemed to be withdrawn | published on 19.12.2012 [2012/51] | Applicant(s) | For all designated states Kornbluth, Richard S. 5415 Taft Avenue La Jolla, CA 92037 / US | [2009/49] | Inventor(s) | 01 /
see applicant ... | [2009/49] | Representative(s) | Grund, Martin Grund Intellectual Property Group Patentanwälte und Solicitor PartG mbB Steinsdorfstraße 2 80538 München / DE | [N/P] |
| Former [2009/49] | Grund, Martin Grund Intellectual Property Group Nikolaistrasse 15 80802 München / DE | Application number, filing date | 09009445.9 | 20.03.2000 | [2009/49] | Priority number, date | US19990454223 | 09.12.1999 Original published format: US 454223 | [2009/49] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2128174 | Date: | 02.12.2009 | Language: | EN | [2009/49] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 14.10.2009 | Classification | IPC: | C07K14/525, C07K14/705 | [2009/49] | CPC: |
C07K14/525 (EP,US);
C07K14/70575 (EP,US);
A61K39/00 (EP,US);
C07K2319/00 (EP,US)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2009/49] | Title | German: | Multimere Formen von TNF-Superfamilienliganden | [2009/49] | English: | Multimeric forms of TNF superfamily ligands | [2009/49] | French: | Formules multimères de ligands de famille élargie de TNF | [2009/49] | Examination procedure | 18.05.2010 | Examination requested [2010/26] | 28.06.2010 | Despatch of a communication from the examining division (Time limit: M04) | 27.10.2010 | Reply to a communication from the examining division | 07.02.2012 | Despatch of a communication from the examining division (Time limit: M04) | 19.06.2012 | Application deemed to be withdrawn, date of legal effect [2012/51] | 24.07.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2012/51] | Parent application(s) Tooltip | EP00919485.3 / EP1235853 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000919485) is 18.01.2008 | Fees paid | Renewal fee | 29.10.2009 | Renewal fee patent year 03 | 29.10.2009 | Renewal fee patent year 04 | 29.10.2009 | Renewal fee patent year 05 | 29.10.2009 | Renewal fee patent year 06 | 29.10.2009 | Renewal fee patent year 07 | 29.10.2009 | Renewal fee patent year 08 | 29.10.2009 | Renewal fee patent year 09 | 29.10.2009 | Renewal fee patent year 10 | 22.03.2010 | Renewal fee patent year 11 | 21.03.2011 | Renewal fee patent year 12 | Penalty fee | Additional fee for renewal fee | 31.03.2012 | 13 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] WO9531540 (MEDICAL RES COUNCIL et al.) | [A] WO9904000 (ZYMOGENETICS INC et al.) | [A] WO9410308 (IMMUNEX CORP et al.) | [L] US2005158831 (KORNBLUTH RICHARD S et al.) | [E] WO0149866 (APOTECH RES & DEV LTD et al.) | [A] POUND JOHN D ET AL: "Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells", INTERNATIONAL IMMUNOLOGY, vol. 11, no. 1, January 1999 (1999-01-01), pages 11 - 20, XP002268025, ISSN: 0953-8178 DOI: http://dx.doi.org/10.1093/intimm/11.1.11 | [A] SCHNEIDER P ET AL: "Conversion of membrane-bound FasCD95 ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 187, no. 8, 20 April 1998 (1998-04-20), pages 1205 - 1213, XP002167589, ISSN: 0022-1007 DOI: http://dx.doi.org/10.1084/jem.187.8.1205 | [A] KISHORE UDAY ET AL: "Modular organization of proteins containing C1q-like globular domain", IMMUNOPHARMACOLOGY, vol. 42, no. 1-3, May 1999 (1999-05-01), pages 15 - 21, XP002268027, ISSN: 0162-3109 DOI: http://dx.doi.org/10.1016/S0162-3109(99)00011-9 | [A] SANO HITOMI ET AL: "Analysis of chimeric proteins identifies the regions in the carbohydrate recognition domains of rat lung collectins that are essential for interactions with phospholipids, glycolipids, and alveolar type II cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4783 - 4789, XP002268026, ISSN: 0021-9258 DOI: http://dx.doi.org/10.1074/jbc.273.8.4783 | [A] BROWN-AUGSBURGER PATRICIA ET AL: "Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D: Expression of a trimeric protein with altered anti-viral properties", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 23, 1996, pages 13724 - 13730, XP002547784, ISSN: 0021-9258 DOI: http://dx.doi.org/10.1074/jbc.271.23.13724 | [A] HOPPE H-J ET AL: "A PARALLEL THREE STRANDED ALPHA-HELICAL BUNDLE AT THE NUCLEATION SITE OF COLLAGEN TRIPLE-HELIX FORMATION", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 344, no. 2/3, 1994, pages 191 - 195, XP001061804, ISSN: 0014-5793 DOI: http://dx.doi.org/10.1016/0014-5793(94)00383-1 | [A] KORNBLUTH R S ET AL: "CD40L (CD154) fusion protein with pulmonary surfactant protein D as a prototype for soluble multimeric TNF superfamily ligand molecules", FASEB JOURNAL, vol. 14, no. 6, 20 April 2000 (2000-04-20), Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Societ;Seattle, Washington, USA; May 12-16, 2000, pages A1162, XP009023848, ISSN: 0892-6638 [A] * the whole document * | [A] HASWELL L E ET AL: "Analysis of the oligomeric requirements for signaling by CD40 using soluble multimeric forms of its ligans, CD154", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 31, no. 10, October 2001 (2001-10-01), pages 3094 - 3100, XP002237771, ISSN: 0014-2980 [A] * the whole document * DOI: http://dx.doi.org/10.1002/1521-4141(2001010)31:10<3094::AID-IMMU3094>3.0.CO;2-F | [A] STONE G W ET AL: "Macaque Multimeric Soluble CD40 Ligand and GITR Ligand Constructs Are Immunostimulatory Molecules in Vitro", CLINICAL AND VACCINE IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 13, no. 11, 20 September 2006 (2006-09-20), pages 1223 - 1230, XP002446741, ISSN: 1556-6811 [A] * the whole document * DOI: http://dx.doi.org/10.1128/CVI.00198-06 | by applicant | US5155027 | US5716805 | FANSLOW, J. IMMUNOL., vol. 136, 1986, pages 4099 | HOLLENBAUGH ET AL., EMBO J., vol. 11, 1992, pages 4313 | MORRIS ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 418 | SCHNEIDER ET AL., J EXP. MED, vol. 187, 1998, pages 1205 | BAZZONI; BEUTLER, N. ENG/. J. MED, vol. 334, 1996, pages 1717 | POSZKOWSKI ET AL., EMBO J, vol. 3, 1989, pages 2719 | ODELL ET AL., NATURE, vol. 313, 1985, pages 810 | CHUA ET AL., SCIENCE, vol. 244, 1989, pages 174 - 181 | CHUA, SCIENCE, vol. 244, 1989, pages 174 - 181 |